[Skip to Content]

intravitreal injections

Wet AMD patients’ injections and appointments during Coronavirus pandemic

The Royal College of Ophthalmologists and the Macular Society have issued the following important information for patients having treatment for Wet AMD or other conditions needing intravitreal injections during the Coronavirus pandemic The NHS and the government are putting in place changes and recommendations in our daily lives to cope with the Coronavirus situation and

Safety Alert – particulate matter discovered in syringes for intravitreal injections

The College has been approached by a unit concerned about particulate matter discovered in syringes for intravitreal injections. The literature reports that silicone oil droplets have been implicated in the past but this set of cases appears to be linked to particles of syringe plastic material. There are also concerns of a small number of

NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO

College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced